Orchid
Orchid is a reproductive technology company offering whole genome embryo screening (PGT-WGS) for IVF patients and a direct-to-consumer preconception Couple Report for couples planning families, processed in a CAP/CLIA-certified laboratory using proprietary high-depth sequencing and polygenic risk scoring.
- Company typePrivate
- Founded2019
- HeadquartersSan Francisco, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingServices
What Orchid does
Orchid is a reproductive technology company that provides whole genome embryo screening for IVF patients and preconception genetic screening for couples planning families. The company's core technology, PGT-WGS (Preimplantation Genetic Testing for Whole Genome Sequencing), performs high-depth whole genome sequencing on a standard 5-6 cell trophectoderm biopsy to read over 99.6% of an embryo's genome, replacing the <1% coverage of traditional array-based PGT-A. From a single biopsy, the platform delivers an integrated report combining aneuploidy screening (PGT-A), monogenic variant detection (PGT-M) for 1,441 genes including 200+ neurodevelopmental disorders, 1,000+ birth defects, and 90+ cancer predisposition syndromes, structural rearrangement detection (PGT-SR), and polygenic risk scores for chronic conditions. Sample processing is performed in Orchid's CAP-accredited (CAP #9234146) and CLIA-certified (CLIA #34D2260214) laboratory in North Carolina using Illumina NovaSeq6000 sequencers, Lockbox LIMS for sample tracking, and GATK/Sentieon-based bioinformatics pipelines. Clinical validation includes 96.80% genome-wide sensitivity and 97.76% precision against live-born children (ASRM 2025) and 10/10 kinship concordance.
Orchid monetizes through per-embryo testing fees of $2,500 for IVF patients (entirely self-pay, no insurance reimbursement, with CapexMD patient financing available) and through a direct-to-consumer Couple Report preconception saliva kit at $998. Distribution is hybrid: partnered U.S. fertility clinics and reproductive endocrinologists order embryo screening on behalf of IVF patients (clinic onboarding with orientation, biopsy dry run, and sample logistics), while the Couple Report is sold via Orchid's own e-commerce portal and self-serve patient portal at portal.orchidhealth.com. The company serves IVF patients, carrier couples seeking PGT-M, patients using donor gametes, couples planning a family pre-IVF, and advanced paternal age patients concerned about de novo variants. Orchid is headquartered in San Francisco, operates an 11-50 person team, and was founded circa 2019-2020 by CEO Noor Siddiqui.
Orchid has raised approximately $12 million in disclosed venture funding, with backers including Refactor Capital (lead of seed round), Day One Ventures, Village Global, and prominent individual investors Brian Armstrong (Coinbase), Vitalik Buterin (Ethereum), Anne Wojcicki (23andMe), Elad Gil (Color Genomics), George Church (Harvard/MIT), and Carlos Bustamante. The company is licensed to process samples nationwide except New York and is pursuing NY CLEP licensure. Scientific advisors include Stanford-affiliated embryologists and reproductive endocrinologists Jacques Cohen, Barry Behr, Lusine Aghajanova, Jan Liphardt, Amber Cooper, Roohi Jeelani, and Nathan Slotnick. Notable media coverage has appeared in The New York Times, The Wall Street Journal, Wired, The New Yorker, CNBC, Business Insider, and MIT Technology Review.
Orchid firmographics
Firmographics- Name
- Orchid
- Legal name
- Orchid
- Website
- https://orchidhealth.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Orchid is a reproductive technology company offering whole genome embryo screening (PGT-WGS) for IVF patients and a direct-to-consumer preconception Couple Report for couples planning families, processed in a CAP/CLIA-certified laboratory using proprietary high-depth sequencing and polygenic risk scoring.
- Ownership category
- akta.pro rank
Orchid industry classification
Industry- Product category
- Reproductive Genetic Testing
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151), Family Planning Centers (621410)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)
- akta.pro secondary industries
- Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
Keywords
Where Orchid is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Orchid business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Operations
Revenue model
- Embryo screening (PGT-WGS) per-embryo testing fees: One-time, per-embryo fee for whole genome embryo screening performed during IVF; Orchid's standard Preimplantation Whole-Genome Sequencing costs $2,500 per embryo; billed either directly to the patient or to the IVF center. Self-pay only — Orchid does not work directly with insurance providers at this time.
- Couple Report preconception screening kits: Direct-to-consumer saliva-based preconception genetic screening kit priced at $998, including individual reports for each partner and a combined couple report with 1:1 genetic counselor consultation; one-time purchase.
- Recurring volume testing services for fertility clinic partners: Per-cycle, per-embryo testing revenue from partnered fertility clinics/REIs across the U.S.; revenue scales with IVF cycle volume and number of embryos submitted per cycle; sample logistics managed by Orchid.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Couple Report (preconception saliva kit for couples): $998 |
| Unit Pricing | Pay-as-you-go | Embryo screening (PGT-WGS): $2,500 per embryo |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels10 records
Orchid product offering
Product offeringCore offering
Orchid provides whole genome embryo screening for IVF patients through its proprietary PGT-WGS platform, which reads over 99.6% of an embryo's genome from a single trophectoderm biopsy to detect aneuploidy, monogenic conditions, structural rearrangements, and polygenic disease risk. Services are delivered via the integrated Embryo Report (ordered through partnered fertility clinics) and the standalone preconception Couple Report (a $998 at-home saliva kit sold direct to consumers).
Product overview
Orchid offers a unified whole genome embryo screening platform centered on its flagship PGT-WGS (Preimplantation Genetic Testing for Whole Genome Sequencing) technology, delivered through the integrated Embryo Report. The platform combines four technology modules—PGT-WGS, PGT-M (monogenic conditions), PGT-SR (structural rearrangements), and PGT-P (polygenic risk scores)—into a single deliverable from one embryo biopsy, alongside the standalone preconception Couple Report for couples not yet undergoing IVF. All screening is performed in Orchid's CAP/CLIA-certified laboratory in North Carolina and supported by 1:1 board-certified genetic counseling included with every test.
Differentiator
Problem solved
Functional benefit
Brands
- Embryo Report: Orchid's whole genome embryo screening product for IVF embryos (PGT-WGS).
- Couple Report
- Conceivable with Noor
Products and services
- Embryo Report Orchid's flagship integrated whole genome embryo screening report combining PGT-A, PGT-M, PGT-SR, monogenic disease panels (1,441 genes across neurodevelopmental, birth defects, and cancer predisposition), and polygenic risk scores from a single embryo biopsy; screens over 99.6% of an embryo's genome for more than 1,200 conditions and is intended for IVF patients and their fertility clinics.
- PGT-WGS (Preimplantation Genetic Testing for Whole Genome Sequencing) Comprehensive whole genome sequencing test that reads over 99% of an embryo's genome from a standard 5-6 cell trophectoderm biopsy, combining aneuploidy screening, 200+ neurodevelopmental disorder panels, 1,000+ birth defect panels, 90+ cancer predisposition syndromes, polygenic risk scores, and structural rearrangement detection in a single assay with no probe design required; intended for IVF patients and reproductive endocrinologists.
- PGT-M (Preimplantation Genetic Testing for Monogenic conditions) Targeted embryo screening for known single-gene conditions in the family (e.g., BRCA mutations, Spinal Muscular Atrophy, Fragile X Syndrome) without custom probe design, with case acceptance within 24-48 hours and ability to handle challenging cases rejected by other labs; intended for couples with known familial genetic risk undergoing IVF.
- PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements) Detects both balanced and unbalanced chromosomal rearrangements, translocations, and inversions in embryos, uniquely identifying balanced carriers missed by most PGT-SR screens while combining with whole genome insights for hundreds of additional conditions; intended for IVF patients with known parental chromosomal rearrangements.
- Couple Report Preconception genetic screening for couples that quantifies a future child's combined genetic risk for 10+ polygenic conditions including Alzheimer's, breast cancer, schizophrenia, bipolar disorder, type 1 and type 2 diabetes, atrial fibrillation, and others; uses a single at-home saliva collection kit, priced at $998, and includes individual reports plus a combined couple report with 1:1 genetic counselor consultation; intended for couples planning a family before or in lieu of IVF.
Quantifiable outcome
- Screens 1,441 genes linked to genetic disease, covering 200+ neurodevelopmental disorders, 1,000+ birth defects/pediatric conditions, and 90+ cancer predisposition syndromes
- +7 more outcomes
Companies that use Orchid
Customer profileNamed customers10 records
Segments6 records
Ideal customer profiles3 records
Orchid technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability2 records
Feature8 records
Orchid partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered major.
- Third Wave Analytics (Lockbox LIMS)majorOrchid uses Lockbox LIMS, a laboratory information management system (LIMS) designed for clinical laboratories, from Third Wave Analytics. Orchid states it 'maintains the highest standards of clinical workflow compliance and sample tracking using Lockbox LIMS.'
- Illumina (sequencing platform provider)majorOrchid operates Illumina sequencing platforms (e.g., NovaSeq6000) in its North Carolina lab to perform NGS workflows including DNA amplification, purification, library preparation, library quantification, and sequencing. Listed as required hands-on experience for Molecular Laboratory Technologist role.
- Jacques Cohen, PhDmajorOrchid Scientific Advisor. Pioneering Embryologist and foundational figure in IVF and ART innovation. Provides scientific guidance and credibility on embryo screening and reproductive technology.
- Roohi Jeelani, MDmajorOrchid Scientific Advisor. Double board-certified Reproductive Endocrinologist and Infertility Specialist (REI). Provides clinical and scientific guidance for Orchid's embryo screening products.
- Lusine Aghajanova, MD, PhDmajorOrchid Scientific Advisor. Clinical Assistant Professor at the Stanford Medical Center. Provides scientific and clinical expertise in reproductive medicine and embryology.
- Barry Behr, PhDmajorOrchid Scientific Advisor. Professor of Obstetrics and Gynecology Emeritus at the Stanford Medical Center; Emeritus Director of Stanford's IVF Lab. Featured on 'Conceivable with Noor' podcast discussing how IVF embryos are actually made.
- Jan Liphardt, PhDmajorOrchid Scientific Advisor. Professor of Bioengineering at Stanford University. Provides bioengineering expertise related to Orchid's genomic sequencing platform.
- Nathan Slotnick, MD, PhDmajorOrchid Scientific Advisor. Perinatologist and Medical Geneticist. Provides clinical genetics and perinatology guidance for Orchid's screening reports and clinical decision-making.
- Amber Cooper, MDmajorOrchid Scientific Advisor. Double board-certified Obstetrics and Gynecologist and Reproductive Endocrinologist and Infertility Specialist. Provides clinical guidance for Orchid's reproductive medicine products.
Scale indicators12 records
Recent moves6 records
Expansion highlights7 records
Orchid competitors and assessment
Company assessmentEmerging players
- Color Genomics: Color Genomics provides clinical genetic testing for hereditary cancer, cardiac, and pharmacogenomic risk. Elad Gil (Color co-founder) is a personal Orchid investor, and Color's model of population-scale genetic screening aligns with Orchid's vision of broad consumer and clinical access to comprehensive genetic information.
- Sema4 (GeneDx): Sema4 is a clinical genomic testing company focused on reproductive health, hereditary cancer, and rare disease screening. Its reproductive health products overlap with Orchid's IVF and preconception screening positioning, particularly in serving fertility clinics and patients planning a family.
Direct peers
- Genomic Prediction: Genomic Prediction is the most direct competitor to Orchid, offering PGT-P (polygenic embryo screening) alongside traditional PGT-A/PGT-M. Both companies compete for the same fertility clinic channel, target IVF patients seeking expanded genetic risk information, and use whole-genome or high-density genotyping for embryo analysis.
- Nucleus Genomics: Nucleus Genomics is a consumer genetics company offering whole-genome sequencing and polygenic risk scores, including for reproductive and embryo-related applications. It competes directly with Orchid's Couple Report at the consumer level and represents a parallel approach to expanding access to genetic data outside traditional clinical channels.
Broad incumbents
- CooperSurgical: CooperSurgical (a CooperCompanies division) provides IVF lab supplies, PGT services, and reproductive medicine products to fertility clinics globally. As an established B2B supplier to the same fertility centers Orchid is targeting, it represents the incumbent channel partner whose existing PGT relationships Orchid must displace or integrate with.
- 23andMe: 23andMe is a major consumer genetics platform offering ancestry, health, and polygenic risk reports. Anne Wojcicki (23andMe's founder/CEO) is a personal Orchid investor, and 23andMe's consumer genetic testing model is comparable to Orchid's Couple Report DTC offering for genetic risk awareness.
- Myriad Genetics: Myriad Genetics is a major clinical genetic testing company with hereditary cancer, prenatal, and reproductive health products. It serves similar patient populations concerned about inherited disease risk and operates a broader clinical lab infrastructure, making it a relevant broad incumbent comparable to Orchid on the clinical genetics side.
- Fulgent Genetics: Fulgent Genetics is a clinical genetic testing company offering NGS-based panels for reproductive health, hereditary cancer, and pediatric conditions. Its technology platform and clinical lab infrastructure make it a relevant comparable on the lab services side, though Fulgent's scale is substantially larger than Orchid's.
- Natera: Natera is a large, publicly traded genetic testing company offering PGT-A (Spectrum PGT), NIPS (Panorama), and carrier screening products to fertility clinics and OB/GYNs. It is a broad incumbent in the IVF genetic testing space with insurance coverage, established clinic relationships, and significantly greater scale than Orchid.
- Invitae: Invitae is a clinical genetic testing company offering hereditary cancer screening, reproductive health, and proactive genetic testing. It serves similar patient and clinician populations with comprehensive genetic panels, representing a broader incumbent in the clinical genetics services space.
Market position
Strengths3 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Orchid social profiles
Digital presenceOrchid compliance and trust
Trust signalCompliance1 record
Orchid financial estimates
Financial estimateRevenue estimate
Valuation estimate
Orchid leadership team
Management profileNumber of profiles
Profiles9 records
Orchid funding detail
Funding detailFunding overview
Funding rounds4 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Orchid M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Orchid
What does Orchid do?
Orchid provides whole genome embryo screening for IVF patients through its proprietary PGT-WGS platform, which reads over 99.6% of an embryo's genome from a single trophectoderm biopsy to detect aneuploidy, monogenic conditions, structural rearrangements, and polygenic disease risk. Services are delivered via the integrated Embryo Report (ordered through partnered fertility clinics) and the standalone preconception Couple Report (a $998 at-home saliva kit sold direct to consumers).
Is Orchid a public or private company?
Orchid is a private company. It is classified as venture growth investor backed and is currently operating.
When was Orchid founded?
Orchid was founded in 2019. It employs 51 to 100 people.
Where is Orchid based?
Orchid is headquartered in San Francisco, United States, in the North America region.
How does Orchid make money?
Three revenue lines are on record. Embryo screening (PGT-WGS) per-embryo testing fees are the primary driver. The others are couple Report preconception screening kits and recurring volume testing services for fertility clinic partners.
Who are Orchid's main competitors?
Emerging players on record are Color Genomics and Sema4 (GeneDx). Direct peers are Genomic Prediction and Nucleus Genomics. Broad incumbents are CooperSurgical, 23andMe, Myriad Genetics, Fulgent Genetics, Natera and Invitae.
Does Orchid have an API?
No public API is recorded for Orchid.
What industry is Orchid in?
Orchid's product category is Reproductive Genetic Testing. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 541714 and its SIC code is 8071.